Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 606 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo three times a day (TID) Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Three New Ideas to Protect Special Forces From the Stress of High Altitude

NCT02463357
View directory record Official record
Conditions
Mountain Sickness
Interventions
Quercetin, Nifedipine extended release, Methazolamide, Metformin, Placebo, Nitrite
Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Alma, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 6, 2026, 4:22 PM EDT
Not yet recruiting Phase 2 Interventional

Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans

NCT07602166
View directory record Official record
Conditions
Salt Sensitivity of Blood Pressure, High Blood Pressure, Inflammation, Renin-Angiotensin-Aldosterone System
Interventions
2-hydroxybenzylamine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 6, 2026, 4:22 PM EDT
Withdrawn Not applicable Interventional

The Efficacy of SinoFresh Nasal and Sinus Care Nasal Spray in Eliminating MRSA From the Nasal Cavity

NCT00790972
View directory record Official record
Conditions
MRSA Infection
Interventions
Sinofresh, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 6, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease

NCT04817670
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg, Placebo BID, Placebo TID
Drug
Lead sponsor
Vifor (International) Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 6, 2026, 4:22 PM EDT
Completed Phase 2 Interventional

Herbal Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

NCT00100295
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Hypericum perforatum, Placebo
Drug · Other
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
6 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Oct 26, 2007 · Synced Oct 6, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study

NCT01364467
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
Placebo, Guaifenesin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
7 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 6, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease

NCT00391170
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Topical Dexamethasone, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
12 Years to 110 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 6, 2026, 4:22 PM EDT
Recruiting Phase 2 Interventional

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

NCT05405387
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Leukemia
Interventions
Budesonide EC, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 6, 2026, 4:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes

NCT01508338
View directory record Official record
Conditions
Healthy Experienced Weight Training Males
Interventions
Placebo, HMB, Peak ATP and HMB, ATP
Dietary Supplement
Lead sponsor
Metabolic Technologies Inc.
Industry
Eligibility
18 Years to 30 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 6, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

ESBA105 in Patients With Severe Dry Eye

NCT01338610
View directory record Official record
Conditions
Eyes Dry Chronic
Interventions
ESBA105 ophthalmic solution, ESBA105 vehicle
Biological · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 6, 2026, 4:22 PM EDT
Not yet recruiting Phase 1 Interventional

Cannabis Effects on Opioid Self-Administration

NCT07668635
View directory record Official record
Conditions
Opioid Use Disorder, Cannabis Use
Interventions
Cannabis, Placebo Cannabis, Intranasal Opioid Agonist, Oral Opioid Agonist
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 6, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics

NCT00605904
View directory record Official record
Conditions
Alcoholism
Interventions
Acamprosate, Yohimbine, mCPP, Saline
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 6, 2026, 4:22 PM EDT
Completed Phase 3 Interventional

A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis

NCT02492321
View directory record Official record
Conditions
Allergic Conjunctivitis (AC)
Interventions
EBI-005, Placebo Comparator
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
11
States / cities
Morrow, Georgia • Louisville, Kentucky • Andover, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 6, 2026, 4:22 PM EDT
Withdrawn Not applicable Interventional

Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients

NCT01812434
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 6, 2026, 4:22 PM EDT
Recruiting Phase 2 Interventional

Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury

NCT06937307
View directory record Official record
Conditions
Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver
Interventions
Droxidopa capsules, Placebo
Drug · Other
Lead sponsor
Giuseppe Cullaro, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 6, 2026, 4:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers

NCT05592951
View directory record Official record
Conditions
Safety, Tolerance
Interventions
Crystal Light (once serving), Liquid IV with amino acids (one serving), Liquid IV with amino acids (two servings), Liquid IV with amino acids (three servings)
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 6, 2026, 4:22 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

NCT05686239
View directory record Official record
Conditions
Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
Interventions
RL-007 (Inidascamine), Placebo
Drug
Lead sponsor
Recognify Life Sciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Culver City, California • Garden Grove, California • Lafayette, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 6, 2026, 4:22 PM EDT
Completed Phase 4 Interventional Results available

Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment

NCT00798577
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Vigamox Ophthalmic Solution, BSS placebo
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Year and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2010 · Synced Oct 6, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Results available

Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial

NCT04839354
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
L-Arginine Hydrochloride, Normal saline
Drug · Other
Lead sponsor
Claudia R. Morris
Other
Eligibility
3 Years to 21 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 6, 2026, 4:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Prospective Study Investigating the Effects of a Novel Weight Management Program

NCT01875354
View directory record Official record
Conditions
Overweight
Interventions
Dietary Supplements and TR90 Eating Plan, Placebo and Low Fat Eating Plan
Dietary Supplement
Lead sponsor
Pharmanex
Industry
Eligibility
18 Years to 65 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Logan, Utah
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 6, 2026, 4:22 PM EDT
Completed Phase 2Phase 3 Interventional

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

NCT01670032
View directory record Official record
Conditions
Impetigo
Interventions
Experimental: CD07223 1.5 % Topical Gel BID, Experimental: CD07223 1.5% Topical Gel TID, Placebo Comparator: CD07223 vehicle gel BID, Placebo Comparator: CD07223 vehicle gel TID
Drug
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Bell Gardens, California • Boca Raton, Florida • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Oct 6, 2026, 4:22 PM EDT
Recruiting Phase 2 Interventional

LIFT: Life Improvement Trial

NCT06366724
View directory record Official record
Conditions
ME/CFS, Long COVID, PASC
Interventions
Pyridostigmine, Low-Dose Naltrexone, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 6, 2026, 4:22 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension

NCT00737594
View directory record Official record
Conditions
Portal Hypertension
Interventions
Placebo, Cobiprostone
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 6, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

GSK2982772 Study in Subjects With Ulcerative Colitis

NCT02903966
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
GSK2982772, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Moreno Valley, California • San Diego, California • Marrero, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 6, 2026, 4:22 PM EDT